Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01110174 · ClinicalTrials.gov registry record · NA

Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms

A NA study of Breast Cancer, sponsored by University of California, Davis.

Completed
Registry status
NA
Development phase
8
Enrollment target
1
Study location

NCT01110174: Completed NA study of Breast Cancer, sponsored by University of California, Davis.

NCT01110174 is a NA study of Breast Cancer that has completed, run by University of California, Davis. The registered enrollment target is 8 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01110174, a NA study of Breast Cancer, has completed, sponsored by University of California, Davis.

COMPLETED
Registry status
NA
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

A pilot study of adult (≥ 18 years) women with stage II-III breast cancer who will receive preoperative chemotherapy prior to mastectomy. Patients will have real-time serum glycan profiling, expression of tissue MUC 1 oncoprotein isoforms to predict neoadjuvant chemotherapy response and additional mammography and HD PET/CT examinations to assess response. The investigators hypothesize that a functional tumor assessment utilizing high-definition positron emission tomography/computed tomography (HD PET/CT), real-time serum glycan profiling, and expression of tissue MUC 1 oncoprotein isoforms will predict neoadjuvant chemotherapy response in breast cancer patients.

Primary Outcome

Patients will have a HD PET/CT at baseline and another after the first cycle of NAC and upon completion.The goal is to distinguish NAC responders from non-responders and to accurately identify the size and extent of residual disease.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST HD PET/CT

Study Locations (1)

California

  • University of California, Davis Medical Center - Sacramento

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2010-03
Est. Completion 2016-03
Phase NA
University of California, Davis

657 total trials

What the finished NCT01110174 record still lists

NCT01110174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which HD PET/CT is the first listed.

NCT01110174 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01110174 about?

NCT01110174 is a clinical study titled "Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms". A pilot study of adult (≥ 18 years) women with stage II-III breast cancer who will receive preoperative chemotherapy prior to mastectomy. Patients will have real-time serum glycan profiling, expression of tissue MUC 1 oncoprotein isoforms to predict neoadjuvant chemotherapy response and additional m...

What is the current status of trial NCT01110174?

This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2010-03. Estimated completion is 2016-03.

What conditions does trial NCT01110174 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT01110174?

The interventions under investigation include: HD PET/CT (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT01110174?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01110174 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01110174's enrollment target sits among peer trials

8 1196th of 1224 higher than 24 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01110174, the US trial registry maintained by the National Library of Medicine. NCT01110174 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.